利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤疗效分析

摘要

目的：探讨利妥昔单抗联合CHOP 方案对非霍奇金淋巴瘤的临床疗效。方法：48例非霍奇金淋巴瘤患者被随机分为两组，对照组行CHOP方案治疗；实验组在CHOP 方案基础上，联合利妥昔单抗治疗；比较两组化疗效果及不良反应。结果：实验组中完全缓解（ CR）11例，部分缓解（ PR）8例，总有效率为79．2％；对照组中完全缓解（ CR）7例，部分缓解（ PR）6例，总有效率为54．2％；实验组的有效缓解率明显高于对照组，差异显著，具有统计学意义（P＜0．05）；但实验组不良反应的发生率与对照组无明显差异（ P＞0．05）。结论：利妥昔单抗联合CHOP方案治疗非霍奇金淋巴瘤的临床效果明显优于单一采用CHOP化疗方案，且联合用药并不会增加并发症的发生，适合于临床一线治疗。%Objective:To investigate the effect of rituximab combined with CHOP for non-Hodgkin's lymphoma .Methods:48 patients with non-Hodgkin's lymphoma were divided into experimental group ( 24 cases) and control group (24 cases) randomly.The patients in control group were treated with CHOP regi-men alone, and those in experimental group received rituximab combined with CHOP regimen.The response rate and adverse reaction were compared between two groups .Results: Patients got complete remission (CR) and partial remission (PR) were 11 cases and 8 cases, and total response rate was 79.2%in experi-mental group.And the numbers were 7 cases and 6 cases, and total response rate was 54.2% in control group.The therapeutic differences between two groups showed a statistical significance (P<0.05).But the rates of adverse reaction was similiar ( P>0 .05 ) .Conclusion: Compared with CHOP regimen chemothera-py, rituximab combined with CHOP regimen shows better therapeutic effect without creasing the adverse re-action.